Inhaled Mebufotenin (GH001) for Adult Patients With Postpartum Depression: A Phase 2a Open-Label Clinical Trial.
The Journal of Clinical Psychiatry June 3, 2026 Martin Johnson, Pau Aceves Baldo, Emilio Arbe et al.
Objective: Postpartum depression (PPD) is a debilitating mood disorder with peripartum onset. Current treatment options are limited in PPD. GH001 is a synthetic inhalation formulation of the psychoactive molecule mebufotenin (5-MeO-DMT). This trial investigated the preliminary efficacy and safety of GH001 in adult females with PPD. Methods: This phase 2a, proof-of-concept, open-label trial...